Form 4: SVP Yen Sells SLNO Shares for Tax Obligations

Kristen Yen, SVP of Global Clinical Operations and Patient Advocacy at Soleno Therapeutics, disposed of 904 shares of common stock to cover tax liabilities from RSU vesting.

Summary

• Kristen Yen, SVP Global Clinical Operations and Patient Advocacy at Soleno Therapeutics Inc. (SLNO), reported a transaction on December 15, 2025.
• Yen disposed of 904 shares of common stock at a price of $49.95 per share.
• This disposition was to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) on the same date.
• Following this transaction, Yen beneficially owns 27,239 shares of common stock, which includes certain RSUs.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction where an executive disposed of shares to cover tax obligations upon the vesting of Restricted Stock Units. This is a standard compensation event and does not indicate any discretionary selling or significant change in company fundamentals, thus leaning neutral to slightly positive due to the RSU vesting.

Positives

• Vesting of Restricted Stock Units (RSUs) for Kristen Yen, indicating a successful compensation event.

Negatives

• Disposition of 904 shares of common stock, reducing direct holdings, although for tax purposes.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• Shares have been withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ('RSUs') which vested on December 15, 2025.

Industry Context

This filing details a routine insider transaction related to executive compensation, specifically the tax withholding associated with the vesting of Restricted Stock Units. Such transactions are common across all industries for publicly traded companies that utilize equity-based compensation plans.

Comparison to Industry Standards

• The practice of withholding shares to cover tax obligations upon the vesting of equity awards like RSUs is a standard and widely adopted compensation and tax compliance mechanism across global industries, including biotechnology and pharmaceuticals, where Soleno Therapeutics operates.
• This transaction aligns with typical executive compensation structures seen in companies comparable to Soleno Therapeutics, which often include a significant equity component to align management incentives with shareholder interests.

Related Party Transactions

• The issuer withheld 904 shares of common stock from Kristen Yen, an SVP, to satisfy tax withholding obligations related to the vesting of her Restricted Stock Units.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and involves a small number of shares relative to the company's total outstanding shares.
• Employees: Reflects standard equity compensation practices for executives, indicating the realization of previously granted equity awards.

Key Dates

Recommendation

This Form 4 details a routine, non-discretionary sale of shares by an executive to cover tax obligations upon RSU vesting. It does not provide new information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a reason to buy or sell.

Keywords

Soleno Therapeutics, SLNO, Form 4, Insider Transaction, Kristen Yen, Restricted Stock Units, RSU Vesting, Tax Withholding, Common Stock